文献速递泌尿男性生殖肿瘤

锕-225-PSMA放射性配体治疗转移性去势抵抗性前列腺癌(WARMTH Act):一项多中心回顾性研究

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
PubMed 文献 · Lancet Oncol · 2024-01-11

这项多中心回顾性研究纳入澳大利亚、印度、德国和南非七个中心的488例转移性去势抵抗性前列腺癌(mCRPC)患者,接受至少一个周期的8 MBq锕-225-PSMA放射性配体治疗。中位随访9.0个月,中位总生存期15.5个月(95%CI 13.4-18.3),中位无进展生存期7.9个月(95%CI 6.8-8.9)。347例有口干信息的患者中236例(68%)在首个周期后报告口干;3级或以上贫血64例(13%),白细胞减少19例(4%),血小板减少32例(7%),肾毒性22例(5%),未记录严重不良事件或治疗相关死亡。

要点

  • 225Ac-PSMA放射性配体治疗在经多线治疗的mCRPC中显示抗肿瘤活性,中位总生存期15.5个月。
  • 口干常见,347例可评估患者中236例(68%)在首周期后报告口干。
  • 3级或以上贫血13%、白细胞减少4%、血小板减少7%、肾毒性5%,无治疗相关死亡。

核心结论

  • 225Ac-PSMA放射性配体治疗在mCRPC中显示出显著的抗肿瘤效果,对于已接受过既往批准药物治疗的患者是一种可行的治疗选择。
  • 口干是常见副作用,严重的骨髓和肾脏毒性是较少见的不良事件。

研究设计与样本

  • 这项回顾性研究纳入澳大利亚、印度、德国和南非七个中心的连续患者,任何年龄和ECOG体能状态,组织病理学确诊前列腺腺癌,接受一个或多个周期的8 MBq 225Ac-PSMA放射性配体治疗(静脉给药)用于mCRPC。
  • 既往mCRPC治疗线包括紫杉烷类化疗、雄激素受体轴抑制剂、镥-177(177Lu)PSMA放射性配体治疗和氯化镭-223。
  • 主要结局为总生存期和无进展生存期。

主要发现

  • 2016年1月1日至2023年5月31日,488例mCRPC男性接受了1174个周期的225Ac-PSMA放射性配体治疗(中位2个周期,IQR 2-4)。
  • 患者平均年龄68.1岁(SD 8.8),基线前列腺特异性抗原中位数169.5 ng/mL(IQR 34.6-519.8)。
  • 既往治疗线:多西他赛324例(66%),卡巴他赛103例(21%),阿比特龙191例(39%),恩扎卢胺188例(39%),177Lu-PSMA放射性配体治疗154例(32%),氯化镭-223 18例(4%)。
  • 中位随访时间9.0个月(IQR 5.0-17.5);中位总生存期15.5个月(95%CI 13.4-18.3),中位无进展生存期7.9个月(95%CI 6.8-8.9)。
  • 488例患者中347例(71%)有治疗引起的口干信息,其中236例(68%)在首个周期后报告口干;所有接受超过七个周期的患者均报告口干;3级或以上贫血64例(13%)、白细胞减少19例(4%)、血小板减少32例(7%)、肾毒性22例(5%);未记录严重不良事件或治疗相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Actinium-225 (225Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of 225Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the world. METHODS: This retrospective study included patients treated at seven centres in Australia, India, Germany, and South Africa. We pooled data of consecutive patients of any age and Eastern Cooperative Oncology Group performance status with histopathologically confirmed adenocarcinoma of the prostate who were treated with one or more cycles of 8 MBq 225Ac-PSMA RLT administered intravenously for mCRPC. Previous lines of mCRPC treatment included taxane-based chemotherapy, androgen-receptor-axis inhibitors, lutetium-177 (177Lu) PSMA RLT, and radium-223 dichloride. The primary outcomes were overall survival and progression-free survival. FINDINGS: Between Jan 1, 2016, and May 31, 2023, 488 men with mCRPC received 1174 cycles of 225Ac-PSMA RLT (median two cycles, IQR 2-4). The mean age of the patients was 68·1 years (SD 8·8), and the median baseline prostate-specific antigen was 169·5 ng/mL (IQR 34·6-519·8). Previous lines of treatment were docetaxel in 324 (66%) patients, cabazitaxel in 103 (21%) patients, abiraterone in 191 (39%) patients, enzalutamide in 188 (39%) patients, 177Lu-PSMA RLT in 154 (32%) patients, and radium-223 dichloride in 18 (4%) patients. The median follow-up duration was 9·0 months (IQR 5·0-17·5). The median overall survival was 15·5 months (95% CI 13·4-18·3) and median progression-free survival was 7·9 months (6·8-8·9). In 347 (71%) of 488 patients, information regarding treatment-induced xerostomia was available, and 236 (68%) of the 347 patients reported xerostomia after the first cycle of 225Ac-PSMA RLT. All patients who received more than seven cycles of 225Ac-PSMA RLT reported xerostomia. Grade 3 or higher anaemia occurred in 64 (13%) of 488 patients, leukopenia in 19 (4%), thrombocytopenia in 32 (7%), and renal toxicity in 22 (5%). No serious adverse events or treatment-related deaths were recorded. INTERPRETATION: 225Ac-PSMA RLT shows a substantial antitumour effect in mCRPC and represents a viable therapy option in patients treated with previous lines of approved agents. Xerostomia is a common side-effect. Severe bone marrow and renal toxicity are less common adverse events. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024. PMID: 38218192. doi:10.1016/S1470-2045(23)00638-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。